

This PANNA newsletter will also be available at the website: www.pannastudy.com

A newsletter will be issued once per 4 months to update you on the status of the study and inclusions.

Centres

All centres in *The Netherlands; UK; Italy; Germany; Belgium; Ireland; Spain* are open for inclusion.

Canada: ethics approval.



List of compounds under investigation

panna

Etravirine, Intence, ETV
Emtricitabine, Emtriva or FTC
Tenofovir, Viread, TDF
Atazanavir, Reyataz, ATV
Fosamprenavir, Telzir, FPV
Darunavir, Prezista, DRV
Tipranavir, Aptivus, TPV
Indinavir, Crixivan, IDV
Raltegravir, Isentress, RAL
Enfuvirtide, Fuzeon, T-20
Maraviroc, Celsentri, MVC
Efavirenz, Stocrin, EFV*
*UK/Ireland only

Inclusions

73 subjects signed informed consent.



Atazanavir (300/100mg QD) arm closed now!

The atazanavir 300/100mg QD arm is complete. Patients on this regimen **cannot be included** anymore.

HIV PK workshop poster

The first results of tenofovir have been presented as a poster at the HIV PK workshop in Barcelona.

Both the CROI and HIV PK workshop poster are accessible through the website.

Amendment 3

We have written a protocol amendment to include rilpivirine and abacavir to the list of compounds to be investigated in PANNA. And to include two satellite sites in the UK. The amendment has been submitted to ethics committees and national authorities.

I will inform you when the approvals have been obtained and the amendment is active in your country.

Investigator's meeting

We would like to plan an investigator's meeting preferably during CROI 2013, or the Glasgow meeting in November 2012. Please return the email to confirm your presence at these meetings.

Plans

A publication on tenofovir/emtricitabine is being prepared. This will be sent to you for review in July.

We plan to write a joint abstract on maraviroc with the IMPAACT group for CROI 2013.

Have a nice holiday!

Angela and David

Angela Colbers
Project manager
E-mail: A.Colbers@akf.umcn.nl
Radboud University Nijmegen Medical Centre, Internal postal code 864,
Department of Pharmacy,
P.O. Box 9101, 6500 HB Nijmegen
Phone: + 31 (0)24 - 361 64 05
Fa x: + 31 (0)24- 366 87 55